The clinical spectrum and causal relationship assessment of checkpoint inhibitor‐associated autoimmune diabetes mellitus (CIADM): A retrospective observational study

Authors:

Abstract
Aims: This study aims to characterize the clinical spectrum, elucidate the temporal relationship and assess the causality of checkpoint inhibitor‐associated autoimmune diabetes mellitus (CIADM) in a cohort of patients receiving anti‐programmed cell death‐1 (PD‐1)/anti‐programmed death ligand‐1 (PD‐L1) inhibitor therapy. Methods: Individuals who developed CIADM were identified among 4382 hospitalized patients receiving PD‐1/PD‐L1 inhibitor therapy between 2020 and 2024. Demographic characteristics, oncological history, immune checkpoint inhibitor regimens, laboratory parameters (including glycemic control, C‐peptide and islet autoantibodies) and clinical outcomes were systematically collected. Causality was evaluated using the Naranjo algorithm. Results: Among 4382 patients who received PD‐1/PD‐L1 inhibitors, seven (0.16%) were diagnosed with CIADM during the study period. Seven patients were predominantly male, with a median age of 52 years (range: 44–62), and hepatocellular carcinoma was the most common primary malignancy (3/7). All patients developed CIADM after a median of 8 cycles (range: 5–23) of PD‐1/PD‐L1 inhibitors (sintilimab, camrelizumab, envafolimab or atezolizumab). Notably, 86% (6/7) of patients presented with diabetic ketoacidosis (DKA) at onset. Severe pancreatic β‐cell dysfunction was universal, with undetectable fasting and postprandial C‐peptide levels. Islet autoantibodies were positive in only one patient. The Naranjo score indicated a ‘probable’ to ‘highly probable’ causal relationship in all cases. All patients required lifelong insulin therapy. Following glycemic stabilization, immunotherapy was successfully reinitiated in six patients without exacerbating hyperglycemia. Conclusion: CIADM is a severe immune‐related adverse event (irAE) characterized by abrupt onset, a high rate of DKA, and profound insulin deficiency, often in the absence of conventional islet autoantibodies. A definitive causal link exists between PD‐1/PD‐L1 inhibitors and CIADM. Our findings underscore the necessity for proactive glycemic monitoring in patients undergoing ICI therapy, especially in populations such as middle‐aged males with cancers known to have specific demographic profiles (e.g., hepatocellular carcinoma). Importantly, the resumption of immunotherapy is feasible with careful management, highlighting the critical role of a multidisciplinary approach to optimize oncological and metabolic outcomes.
Funding Information
  • Key Research and Development Projects of Shaanxi Province
  • Natural Science Basic Research Program of Shaanxi Province

This publication has 23 references indexed in Scilit: